Description

PNC-27 5mg × 10 vials

A synthetic p53-derived research peptide studied for oncology-related models, HDM-2 interaction pathways, cancer-cell membrane research, pore-formation mechanisms, tumor-cell necrosis models, mitochondrial disruption, and broader cancer-cell biology research protocols.

Product Overview

Compound: PNC-27
Strength: 5 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 5 mg
BAC water: 2 mL
Amount per unit: 25 mcg per unit

Research Dose

Protocol dependent.

Notes

PNC-27 is described as a synthetic peptide containing a p53-derived HDM-2-binding domain linked to a membrane-penetrating peptide sequence. It has been studied for its interaction with HDM-2 expressed on cancer-cell membranes.

Research literature has examined PNC-27 in relation to transmembrane pore formation, cancer-cell membrane disruption, tumor-cell necrosis, mitochondrial disruption, and selective cancer-cell targeting models.

PNC-27 is primarily associated with oncology and cancer-cell biology research. It should not be treated as a general wellness, recovery, or performance peptide.

Most available evidence comes from laboratory and preclinical research, with limited human-context data. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.